HIV-associated neurocognitive disorders: Is there a hidden epidemic?

AIDS

Volumn 24, Issue 9, 2010, Pages 1367-1370

  McArthur, Justin C ^a   Brew, Bruce J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

HIV; HIV Dementia Scale; Neurological disorders

Indexed keywords

ANTIRETROVIRUS AGENT;

CEREBROSPINAL FLUID; COMORBIDITY; DISEASE COURSE; EPIDEMIC; GENETIC RISK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; NEUROLOGIC EXAMINATION; NOTE; PRIORITY JOURNAL; RISK FACTOR;

AIDS DEMENTIA COMPLEX; COGNITION DISORDERS; EPIDEMICS; HIV-1; HUMANS; NEUROPSYCHOLOGICAL TESTS;

EID: 77952902769     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283391d56     Document Type: Note

References (35)

1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neuro-cognitive disorders. Neurology 2007; 69:1789-1799.
2. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289-294.
3. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
4. Clifford DB. Human immunodeficiency virus-associated dementia. Arch Neurol 2000; 57:321-324.
5. Sacktor N, Tarwater PM, Skolasky RL, McArthur JC, Selnes OA, Becker J, et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001; 57:542-544.
6. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004; 61:1699-1704.
7. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cere-brospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
8. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010, 24:1243-1250.
9. Power C, Selnes OA, Grim JA, McArthur JC. The HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr 1995; 8:273-278.
10. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005; 19:1367-1374.
11. McArthur JC, Cohen BA, Selnes OA, Kumar AJ, Cooper K, McArthur JH, et al. Low prevalence of neurological and neu-ropsychological abnormalities in otherwise healthy HIV-1-infected individuals: results from the Multicenter AIDS Cohort Study. Ann Neurol 1989; 26:601-611.
12. Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63:2084-2090.
13. Satz P, Morgenstern H, Miller EN, Selnes OA, McArthur JC, Cohen BA, et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the multicen-ter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1993; 6:503-511.
14. Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner M, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007; 196:361-370.
15. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, et al. Variable progression of HIV-asso-ciated dementia. Neurology 1998; 50:1814-1820.
16. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17:1539-1545.
17. Wong MH, Robertson K, Nakasujja N, Skolasky R, Musisi S, Katabira E, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007; 68:350-355.
18. Wright EJ, Nunn M, Joseph J, Robertson K, Lal L, Brew BJ. NeuroAIDS in the Asia Pacific Region. J Neurovirol 2008; 52: 1-9.
19. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8:33-44.
20. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 (Suppl 2):115-121.
21. Heaton R, Clifford D, Franklin D, Woods S, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders (HAND) persist in the era of potent antiretroviral therapy: The CHARTER Study. Neurology (in press).
22. Cole MA, Margolick JB, Cox C, Li X, Selnes OA, Martin EM, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology 2007; 69:2213-2220.
23. Lopardo GD, Bissio E, Iannella Mdel C, Crespo AD, Garone DB, Cassetti LI. Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:488-492.
24. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21:1915-1921.
25. Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007; 64:97-102.
26. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsy-chological function in HIV-infected HAART-treated patients. Neurology 2006; 66:1447-1450.
27. Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52:607-613.
28. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993; 43:2245-2252.
29. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992; 42:1472-1476.
30. Chiesi A, Seeber AC, Dally LG, Floridia M, Rezza G, Vella S. AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987-1993) and differential incidence according to mode of transmission of HIV-1 infection. J Neurol Sci 1996; 144:107-113.
31. Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry 2008; 20:73-88.
32. Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS 2005; 19:45-52.
33. Singh KK, Ellis RJ, Marquie-Beck J, Letendre S, Heaton RK, Grant I, Spector SA. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol 2004; 157:185-192.
34. Gonzalez E, Rovin BH, Sen L, CookeG, DhandaR, Mummidi S, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002; 99:13795-13800.
35. Mayeux R, Small SA. Finding the beginning or predicting the future? Arch Neurol 2000; 57:783-784.